200 related articles for article (PubMed ID: 22933706)
1. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
[TBL] [Abstract][Full Text] [Related]
2. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Jones RJ; Chen Q; Voorhees PM; Young KH; Bruey-Sedano N; Yang D; Orlowski RZ
Clin Cancer Res; 2008 Sep; 14(17):5416-25. PubMed ID: 18765533
[TBL] [Abstract][Full Text] [Related]
4. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Tabe Y; Sebasigari D; Jin L; Rudelius M; Davies-Hill T; Miyake K; Miida T; Pittaluga S; Raffeld M
Clin Cancer Res; 2009 Feb; 15(3):933-42. PubMed ID: 19188164
[TBL] [Abstract][Full Text] [Related]
5. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
Aziz MH; Shen H; Maki CG
Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
Gu D; Wang S; Kuiatse I; Wang H; He J; Dai Y; Jones RJ; Bjorklund CC; Yang J; Grant S; Orlowski RZ
PLoS One; 2014; 9(9):e103015. PubMed ID: 25181509
[TBL] [Abstract][Full Text] [Related]
10. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
Cheok CF; Kua N; Kaldis P; Lane DP
Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
[TBL] [Abstract][Full Text] [Related]
11. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
12. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
Saha MN; Jiang H; Mukai A; Chang H
Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
[TBL] [Abstract][Full Text] [Related]
13. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
Kurokawa M; Kim J; Geradts J; Matsuura K; Liu L; Ran X; Xia W; Ribar TJ; Henao R; Dewhirst MW; Kim WJ; Lucas JE; Wang S; Spector NL; Kornbluth S
Sci Signal; 2013 May; 6(274):ra32. PubMed ID: 23652204
[TBL] [Abstract][Full Text] [Related]
14. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
17. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
18. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
